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Abstract
Background: Prescription methadone or buprenorphine enables people with opioid use disorder to stop heroin
use safely while avoiding withdrawal. To ensure methadone is taken as prescribed and to prevent diversion onto
the illicit market, people starting methadone take their daily dose under a pharmacist’s supervision. Many patients
miss their daily methadone dose risking withdrawal, craving for heroin and overdose due to loss of heroin
tolerance. Contingency management (CM) can improve medication adherence, but remote delivery using
technology may be resource-light and cost-effective. We developed an innovative way to deliver CM by mobile
telephone. Software monitors patients’ attendance and supervised methadone consumption through an internet
self-login at the pharmacy and sends reinforcing text messages to patients’ mobile telephones. A linked system
sends medication adherence reports to prescribers and provides early warning alerts of missed doses. A pre-paid
debit card system provides financial incentives.
Methods: A cluster randomised controlled trial design was used to test the feasibility of conducting a future trial of
mobile telephone CM to encourage adherence to supervised methadone in community pharmacies. Each cluster
(drug service/3 allied pharmacies) was randomly allocated to provide patient’s presenting for a new episode of
opiate agonist treatment (OAT) with either (a) mobile telephone text message CM, (b) mobile telephone text
message reminders, or (c) no text messages. We assessed acceptability of the interventions, recruitment, and follow-
up procedures.
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Results: Four drug clinics were approached and three recruited. Thirty-three pharmacists were approached and 9
recruited. Over 3 months, 173 individuals were screened and 10 enrolled. Few patients presented for OAT and high
numbers were excluded due to receiving buprenorphine or not attending participating pharmacies. There was 96%
consistency in recording medication adherence by self-login vs. pharmacy records. In focus groups, CM participants
were positive about using self-login, the text messages, and debit card. Prescribers found weekly reporting, time
saving, and allowed closer monitoring of patients. Pharmacists reported that the tablet device was easy to host.
Conclusion: Mobile telephone CM worked well, but a planned future trial will use modified eligibility criteria
(existing OAT patients who regularly miss their methadone/buprenorphine doses) and increase the number of
participating pharmacies.
Trial registration: The trial is retrospectively registered, ISRCTN 58958179.
Keywords: Mobile telephone, Contingency management, Medication adherence, Opioid agonist treatment
Key messages regarding feasibility
What uncertainties existed regarding the feasibility?
 The accuracy of patient self-login of their own at-
tendance/consumption compared with pharmacy
records.
 The ability to recruit the target population.
 The acceptability of delivering CM by mobile
telephone to staff, patients, and pharmacists.
 The choice of primary outcomes for the trial.
What are the key feasibility findings?
 There was a high level of agreement between
patient self-login of attendance and the pharmacy
records.
 That patient self-login, the delivery of CM by mobile
telephone, and incentives via pre-paid debit cards
were feasible.
 Mobile telephone delivered CM was well-liked
by patients and staff and acceptable to
pharmacists.
 Staff reported that the automated weekly reporting
allowed for close monitoring of patients and saved
time not having to call pharmacists.
 Recruitment of the target population was not
feasible; fewer individuals than expected presented
for a new episode of opioid agonist treatment
(OAT), were prescribed methadone, or attended one
of the three participating pharmacies.
What are the implications of the feasibility findings for
the design of the main study?
 The target population should not be restricted to
such a discrete patient group but instead be
modified to include existing patients of OAT who
are regularly missing their doses of methadone and
buprenorphine
 The number of pharmacies recruited should be
increased to ensure the patients are able to
participate in the trial.
 The feasibility of revised recruitment procedures
and recruitment from this wider population should
be assessed with an internal pilot study.
Background
The majority of those with an opioid addiction are pre-
scribed opioid agonist treatment (OAT) with methadone
or buprenorphine for which there is an extensive evi-
dence base [1, 2]. In 2016/2017, there were an estimated
314,000 opioid users in England and Wales of whom ap-
proximately 155,000 were in treatment [3]. However, re-
covery from opioid use disorder is a long-term process
and many heroin users relapse leading to OAT having
high attrition rates [4]. Patients in OAT are often not
achieving abstinence from heroin or other clinical bene-
fits due to non-adherence to medication. Methadone
and buprenorphine need to be taken on a daily basis in
order to achieve effective maintenance and enable pa-
tients to stop heroin use safely and without experiencing
excessive symptoms of withdrawal or craving. The De-
partment of Health [5] recommends methadone con-
sumption is supervised in the early stages of treatment
in order to improve adherence, safeguard against over-
dose, and prevent potential for diversion onto the illicit
market. Patients starting methadone usually take a daily
dose under a community pharmacist’s supervision. A
network of pharmacies dispensing OAT medication ex-
ists across England. A substantial number of patients oc-
casionally fail to attend the pharmacy to take their
methadone with some patients missing multiple doses
[6]. Missed doses are likely to lead to withdrawal symp-
toms and cravings which may lead to heroin use. For
OAT patients, each missed dose is of concern. After 3
days missed doses, there is the risk of loss of tolerance
to opioids and risk of overdose when the next dose is
taken [5]. Consequently, a pharmacist is normally ad-
vised to withhold the next day’s dose if a patient has
missed three consecutive days, and consult with the pre-
scriber prior to supply. Given this, an additional concern
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is the pharmacist’s lack of consistent reporting to the
prescriber about patient’s missed doses. Ten per cent of
pharmacists in England stated they would “never” or
“rarely” report one or two missed doses to prescribers
but would “usually” report three missed doses [6].
The National Institute for Health and Care Excellence
(NICE) recommended that contingency management
(CM) be used in UK drug treatment settings to reduce
drug use and encourage medication adherence [7]. CM
is a behavioural intervention, based on the principles of
operant conditioning, and involves the systematic appli-
cation of positive reinforcement to promote positive be-
haviour consistent with treatment goals [8]. CM has a
large evidence base for its effectiveness in the treatment
of substance misuse [9–11]. A recent systematic review
of studies using CM/incentives to reinforce medication
adherence, but not for OAT, concluded that CM/incen-
tive-based interventions are promising but understudied
[12]. While delivering CM can be time-consuming for
healthcare professionals and requires integration into
healthcare organisational systems, CM delivered by tech-
nology might be a resource-light and cost-effective alter-
native to encourage medication adherence. A systematic
review and a meta-analysis of CM delivered by mobile
telephone, while finding no prior studies targeting OAT
specifically, found CM to be effective [13].
This study focuses on an innovative intervention we
have developed to encourage medication adherence by
delivering CM via mobile telephone text messages, with
a linked system for monitoring and reporting patients’
attendance to prescribers, including early warning alerts
of missed doses [14]. It potentially offers considerable
benefit for patients, drug treatment services, the NHS,
and community pharmacies in the form of a more easily
delivered and less resource-intensive intervention.
Our research aimed to investigate the feasibility of
conducting a future RCT of the clinical and cost-
effectiveness of CM delivered by mobile telephone to en-
courage adherence to supervised consumption of metha-
done at community pharmacies among individuals
receiving OAT. We also conducted a process evaluation
to investigate the acceptability of trial and intervention
procedures and to explore factors influencing the pat-
tern of outcomes which we have reported on here.
Methods
Study design
This was a three-arm cluster randomised feasibility trial
comparing (1) mobile telephone text message CM
(MTCM) or (2) mobile telephone text message re-
minders (MTR) with (3) no telephone text messages
(treatment-as-usual) (TAU). To investigate the feasibility
of conducting a future RCT, research objectives investi-
gated (a) the willingness of clusters (drug clinics and
allied pharmacies) to be randomised, (b) the numbers of
eligible patients, (c) rates of recruitment and recruitment
procedures, (d) the acceptability of the study to patients,
(e) the accuracy of recording/logging in of attendance at
the pharmacy, (f) rates of follow-up at 12 weeks, (g) dif-
ferent options for quantifying the primary outcome
measure, (h) characterising aspects of the primary out-
come measure needed for a sample size calculation for
future trial, and (i) the most appropriate secondary out-
come measures to determine patient benefit and cost-
effectiveness and the availability and usefulness of exist-
ing data sets (including pharmacy dispensing data). In
addition, contextual factors and treatment process that
may impact on outcome were investigated to inform the
design of a definitive trial. More detail is provided in the
protocol [15].
Setting
Three drug services (clusters) were recruited from both
National Health Service (NHS) (South London and
Maudsley NHS Foundation Trust) and non-NHS
(“Change, Grow, Live”, London) services and randomly
allocated to one of the three arms. Three allied commu-
nity pharmacies were recruited for each drug service.
This was increased from the original target of two after
identifying the large numbers of pharmacies providing
supervised oral methadone to patients at the participat-
ing drug services. Drug services were eligible if they pro-
vided OAT where methadone was dispensed for daily
supervision at local community pharmacies. Community
pharmacies were eligible if pharmacists were willing and
able to provide 6 days supervised consumption of oral
methadone, the pharmacy had a consultation room on
the premises or a separate designated area on the dis-
pensing counter in which participants could consume
their oral methadone under supervision, the pharmacy
was currently providing supervised consumption of oral
methadone to the patients at the drug clinic, and the
pharmacy was willing and able to provide dispensing re-
cords for participants over the 12-week intervention
period. Within each cluster (drug treatment service),
participants received the same treatment allocation to
minimise the risk of contamination between intervention
and control arms.
Participants
Participants were recruited by drug service staff from pa-
tients starting a new episode of OAT (including those
newly presenting to the drug service as well as existing
patients at the service who were re-starting OAT after
not receiving a prescription for ≥ 4 weeks) who were re-
ceiving supervised oral methadone at the community
pharmacy 6 days a week. Eligible participants included
the following: aged > 18 years, prescribed oral
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methadone, supervised 6 days a week at a participating
community pharmacy, owned a mobile phone, and will-
ing and able to provide informed consent. Exclusion cri-
teria included the following: patients unable to read
English and would require the service of an interpreter
to understand a brief oral description of the study. These
individuals were excluded because the two active inter-
ventions (mobile telephone text message CM and mobile
telephone text message reminders) required participants
to be able to read text messages in English. The trial was
reviewed by the London South East Research Ethics
Committee and received a favourable opinion on 23 No-
vember 2018.
Sample size
One of the aims of the feasibility trial was to estimate
parameters needed for a sample size calculation for a
larger confirmatory trial. Therefore, no formal sample
size calculations were undertaken but we aimed to re-
cruit 60 consenting patients (20 per drug service).
Processes, interventions, and comparisons
The three drug services were allocated to the three treat-
ment arms using simple randomisation (a 1:1:1 alloca-
tion ratio) with sequences generated using a random
number generator. The senior statistician (KG) was blind
to treatment allocation, but all other members of the
study team, individual participants, and staff at the drug
service and pharmacy were unblind.
Interventions
In all arms, over the 12-week intervention period, OAT
was delivered in line with existing service protocols and
participants used a self-service internet login at the
pharmacy to record their attendance and consumption
of methadone. There were two active arms (MTCM and
MTR) and one treatment-as-usual arm (TAU). In the
two active arms, the mobile telephone-based software
monitored patients’ attendance and supervised metha-
done consumption through the internet self-login at the
pharmacy and contacted patients via text message. A
linked system monitored and reported patient’s attend-
ance and provided early warning alerts of missed doses
to patients’ prescribers. In the MTCM arm, financial in-
centives were delivered via pre-paid debit cards.
Mobile telephone text
message CM (MTCM)
Each time a participant attended the
pharmacy and consumed their supervised
oral methadone, they received a text
message giving praise and earned a
financial reward of 50p. If they attended
for 6 days consecutively, they earned a
bonus reward of £5. The total possible
financial reward was £8/week or £96 over
12 weeks. Patients were paid directly via a
Bread4Business debit card. If they failed to
Interventions (Continued)
attend, participants received a “shaping
text message” informing them they can
still earn 50p if they attend the pharmacy
and take their dose the next day.
Mobile telephone text
message reminders (MTR)
Participants were reminded via text
message each morning and afternoon (if
they failed to attend in the morning) to
attend their pharmacy for their supervised
medication.
Treatment-as-usual (TAU) Participants received no text messages.
The text message CM or reminders were paused if a
participant failed to attend and consume their dose on
three consecutive days, in line with clinical guidance,
and were re-started again when the participant was re-
instated on their methadone. Prescribers at clinics allo-
cated to MTCM or MTR received weekly reports via
email of patient attendance and an early warning if a pa-
tient failed to attend 2 days in-a-row.
Data collection and outcome measures
There were four methods of data collection. First, the
mobile telephone text message system recorded whether
participants logged in each day via the tablet computer
in the pharmacies. Second, pharmacy dispensing/
supervision records—PharmOutcomes—a web-based
system for capturing information on pharmacies services
and financial tracking [16] relating to participants, were
anonymised and provided to the research team. Third, a
research interview with participants was undertaken by
the research team at baseline (following consent) and
again at 12–14 weeks post-enrolment (see Fig. 1).
Fourth, as part of the process evaluation, focus groups
were conducted between 10 and 12 weeks post-
enrolment with participants and staff at two of the three
drug services (delivering MTCM and TAU). Interviews
were conducted at the end of the study with pharmacists
at 6 of the 9 pharmacies. Participants received a £10 re-
imbursement for their time and travel at the baseline
and follow-up interview, and at the focus group (if they
attended).
Feasibility outcomes
The primary feasibility outcome was the number of
patients enrolled during each week of the 12-week inter-
vention period, of those presenting for a new episode of
OAT. Secondary feasibility outcomes included the
following:
1. Number of drug services and pharmacies enrolled,
relative to those approached.
2. Percentage of screened patients who were eligible
and consenting to inclusion in the feasibility trial.
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3. The accuracy of measuring pharmacy attendance,
comparing participants’ self-login via tablet com-
puter with the pharmacy record of daily supervised
consumption using PharmOutcomes.
4. Adherence to telephone text message system,
measured as the percentage of participants
responding to a text messages sent weekly asking
whether participants had received text messages in
the previous week.
5. Rates of follow-up at 12–14 weeks.
6. Acceptability of the study to patients.
Outcomes for use in a future confirmatory trial
Potential primary outcomes for use in a future
confirmatory trial included the following:
7. Adherence to medication (using PharmOutcomes).
The percentage of days adhering to medication by
arm was measured as (i) percentage of days during
12-week intervention period when medication was
taken, (ii) median number of days during 12-week
intervention period when medication was not taken,
(iii) Likert-like scale categorising participants by
arm according to different missed dose patterns
during 12 weeks post-enrolment, and (iv) time until
a missed dose.
8. Aspects of the primary outcome measures needed
for a sample size calculation for a future
confirmatory trial including appropriate summary
statistics (for example, mean and standard
deviations for continuous outcomes), an estimate of
the intraclass correlation (ICC) for the clusters, and
qualitative information on the availability and
usefulness of existing pharmacy dispensing data
sets.
Secondary outcomes for use in a future confirmatory
trial included the following:
9. Retention in treatment, measured as the number
and percentage retained in treatment over the 12-
week intervention period.
Fig. 1 Consort diagram
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10. Illicit drug use measured by Opiate Treatment
Index (Section 2—Drug Use) [17].
11. Alcohol Use Disorders Identification Test (AUDIT)
[18].
12. Hospital Anxiety and Depression Scale (HADS) [19].
13. Social functioning measured using the Opiate
Treatment Index (validated, mean social
functioning subscale score) [20].
14. Physical and mental health status (short form-36
subscale mean scores) [21].
15. Sociodemographic characteristics, including age,
gender, ethnicity, employment status, and living
situation.
16. Outcomes for economic evaluation, including
resource use schedules AD-SUS [22], EQ-5D-5L
measure of health-related quality of life [23], and
the ICECAP-A measure of capabilities [24].
Process outcomes
Focus groups with participants and drug service staff
and interviews with pharmacists were conducted to
assess the acceptability of the intervention and trial
procedures and to determine how contextual factors and
treatment process impact on feasibility criteria
(including recruitment, take-up, and compliance with as-
sessments) the primary outcome for a future confirma-
tory trial (medication adherence).
Progression criteria to a future confirmatory trial included
the following:
 Recruitment of three drug services, two to three
pharmacies and 60 participants (20 from each drug
service over 12 weeks).
 50% of target patients (those patients presenting to
participating drug services for a new episode of
OAT who have not been receiving a prescription for
methadone or other OAT medication for > 4 weeks
and who have not been transferred in from another
service or prison) eligible and consented.
 > 95% consistency in recording of pharmacy
attendance (comparing daily pharmacy dispensing
records vs. self-service internet login).
 Rates of follow-up at 12 weeks (> 70%).
 Completion rates of economic data collection (>
70%), missing (item missing/questionnaire missing)
(< 10% missing data per questionnaire), and
inconsistencies.
However, not achieving these criteria does not
necessarily indicate unfeasibility of a future trial but
might underline changes that need to be made to
recruitment procedures, attendance record keeping, and
resources for follow-up.
Statistical and qualitative analysis
Feasibility outcomes were summarised using appropriate
summary statistics (e.g. mean and standard deviation for
normally distributed continuous outcomes; median and
interquartile range for non-normal continuous out-
comes; counts and proportions for categorical out-
comes). The number and percentage of days when the
two assessment methods (self-login via tablet computer
vs. PharmOutcomes) were in agreement was calculated
by (i) enumerating all days during each participant’s 12-
week intervention period; (ii) removing days when the
participant was paused, not supervised, or no longer re-
ceiving OST; and (iii) deriving a binary measure of
agreement (matching = 1; not matching = 0). Appropri-
ate summary statistics were calculated for secondary
outcomes to be explored in a future confirmatory trial.
Missing scale item data was handled as per specific rec-
ommendations for each questionnaire.
For the process evaluation, interviews and focus
groups were based on a topic guide developed iteratively
and applied flexibly to ensure coverage of key issues and
responses to emergent themes. They were coded,




Percentage of drug services and pharmacies enrolled
Between July and December 2018, four drug services
were approached (3 NHS, 1 non-NHS) and three (75%)
were recruited (2 NHS, 1 non-NHS). Thirty-three allied
community pharmacies were approached. Fifteen (46%)
were excluded because they did not provide or rarely
provided supervised consumption of oral methadone to
patients at the drug clinic, and three (9%) did not re-
spond to invitations to discuss the study. Of those eli-
gible and responding (n = 15), nine (60%) were recruited
and six (40%) declined to participate (for unknown
reasons).
Percentage of screened patients who are eligible and
consent to inclusion in the feasibility trial
One hundred and seventy-three patients starting a new
treatment episode were screened for eligibility over a 12-
week period between December 2018 and March 2019.
The start of recruitment was delayed at the drug service
assigned to MTR due to operational issues and recruited
over a 6-week period only. The drug service had difficul-
ties in identifying staff to conduct the screening and
consent procedures. In total, 11 patients were eligible
and 10 enrolled (6% of screened patients) (Fig. 1). One
patient did not consent to participate in the feasibility
trial. Numbers screened and enrolled varied across drug
services: the MTCM arm screened 133 patients (unlike
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the other drug services, it screened those re-starting OAT
after not receiving a prescription for < 4 weeks) and en-
rolled eight (6%); MTR arm screened 36 patients and en-
rolled no patients (0%); and in the TAU arm, four patients
were screened and two enrolled (50%). The most frequent
reasons for exclusion were (a) not a new treatment epi-
sode (MTCM group only) (34%; 55), (b) not receiving oral
methadone (33%; 53), or (c) not attending a participating
pharmacy (19%; 30). Six per cent were ineligible due to
not receiving 6 days a week supervision (6%; 9), 4% not
owning a mobile telephone (4%; 7), four failed to complete
the screening/enrolment process (3%; 4), two were unable
to read English (1%; 2), one was outside the catchment
area (1), and one was unwilling to provide their mobile
telephone number (1).
Sociodemographic characteristics Participants were
typically male (80%; 8), white (80%; 8), aged 41 years on
average, unemployed/receiving sickness benefit (90%; 9),
and living alone (40%; 4). They had all (100%) used
heroin, crack, alcohol, and tobacco in the previous 30
days. Five (50%) were homeless. They had had similar
characteristics to those receiving OAT (Table 1).
The accuracy of measuring pharmacy attendance
Table 2 presents the number and percentage of days
when the two assessment methods were in agreement
(i.e. either both indicating “attended/consumed” or both
indicating “not attended/consumed”). Overall, between
January and June 2019, 96% of days (517/538 days) were
in agreement between both assessment methods (self-
login vs. pharmacy records (PharmOutcomes)).
Adherence to telephone text message system
Overall, most participants did not respond to the
compliance text message (response rates were close to
0%). Due to concerns that poor response may have
been due to the cost involved, an alternative message
system was introduced after recruitment had ended
that made it free for participants to reply, although
responses improved only slightly. However,
participants did contact the study team via the text
message system regarding other issues. Towards the
end of the study, this method of measuring
compliance (i.e. relying on a response from
participants) was supplemented with a more reliable
method whereby the delivery status of all messages
could be categorised retrospectively as “sent/not sent”
and “delivered/not delivered”. Of 500 messages sent
out over the entire study period, 383 (77%) were
successfully delivered to participants. Reasons for
unsuccessful delivery included losing mobile phone,
mobile phone not charged, or mobile phone turned
off to conserve charge.
Rates of follow-up at 12–14 weeks
Three participants stopped receiving the telephone
system early in the study (due to entering inpatient
detox (n = 1), moving to non-participating pharmacy (n
= 1), or unsupervised take-home methadone (n = 1)).
Overall, 9/10 (90%) participants attended follow-up
interviews.
Acceptability to patients, staff, and pharmacists
This is reported under the “Process evaluation” section.
Table 1 Sociodemographic characteristics
Measure MTCM (n = 8) TAU (n = 2) Total (n = 10)
Age Mean (SD) 40.0 (9.6) 44.4 (18.7) 40.9 (10.7)
Gender Female N (%) 1 (12) 1 (50) 2 (20)
Male N (%) 7 (88) 1 (50) 8 (80)
Ethnicity Caribbean N (%) 1 (12) 0 (0) 1 (10)
Other N (%) 0 (0) 1 (50) 1 (10)
Other White N (%) 3 (38) 0 (0) 3 (30)
White British N (%) 4 (50) 1 (50) 5 (50)
Employment status Employed N (%) 0 (0) 1 (50) 1 (10)
Unemployed/sickness benefit N (%) 8 (100) 1 (50) 9 (90)
Living situation Alone N (%) 3 (38) 1 (50) 4 (40)
Family N (%) 1 (12) 0 (0) 1 (10)
Other N (%) 2 (25) 0 (0) 2 (20)
Partner/spouse N (%) 2 (25) 1 (50) 3 (30)
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Primary outcomes for use in a future confirmatory trial
Adherence to medication
Data were available for only 9/10 participants as one
pharmacy was not able to provide PharmOutcomes data
for their one participant. Participants in the MTCM arm
adhered to their medication on 96% (464/485) of days
and TAU on 58% (29/50) of days. The median number
of missed days in the MTCM arm was 2 (IQR 4.5). In
the TAU group, there was a single participant who
missed 21 days in total during the intervention period.
In each of the 12 weeks the telephone system was in use,
most participants (across all arms) had no missed doses
(Table 3). There was insufficient data to carry out
repeated events survival analysis of time until missed
dose.
Aspects of primary outcomes needed for a sample size
calculation
Given the small numbers of participants, and only two
clusters with enrolled participants, it was not possible to
calculate the intraclass correlation for clusters.
Usefulness of data sets
Extracts of data from the telephone system were
automated. In contrast, PharmOutcomes data was
provided by the pharmacies in various formats, making
it necessary for these data to be re-entered into the data-
bases by hand.
Secondary outcomes for use in a future confirmatory trial
The number and percentage of participants retained in
treatment
The number and percentage of participants retained in
treatment (i.e. remaining at the same clinic and still
receiving oral methadone) over the 12-week intervention
period relative to those enrolled can be seen in Table 4.
Nine out of 10 continued to receive treatment at the
same clinic, and 2/10 received a different OST. One par-
ticipant did not attend their follow-up interview.
Illicit drug use and clinical outcomes
Illicit drugs used and clinical outcomes in past 30 days
are presented in the supplementary material. The MTR
group are not presented in these tables because no
participants were enrolled to this arm. No items were
missing in any of the questionnaires.
Health economics
Four items were missing from the baseline AD-SUS
health economics questionnaire addressing service con-
tact; one item at follow-up across all participants. While
we recognise that some feasibility studies do take the
Table 2 Percentage of matches between attendance measured with pharmacy dispensing records (PharmOutcomes) vs. attendance
recorded via self-login on tablet computer
MTCM (n = 8) TAU (n = 1) Total (n = 9)
N (%) days where measures disagree 13 (2.7) 3 (6.0) 16 (3.0)
N (%) days where measures in agreement 472 (96.7) 45 (90.0) 517 (96.1)
N (%) days with missing data (on either measure) 3 (0.6) 2 (4.0) 5 (0.9)
Total days number of active days, all participants 488 50 538
Table 3 Categories of missed response patterns, for each week of intervention period, all arms combined (n = 9)
Week of
intervention
No missed doses Missed 1 or 2 doses Missed 3+ doses Total active participants this week
N (%) N (%) N (%) N
1 8 (89) 1 (11) 0 (0) 9
2 6 (67) 3 (33) 0 (0) 9
3 6 (75) 2 (25) 0 (0) 8
4 5 (71) 1 (14) 1 (14) 7
5 4 (57) 2 (29) 1 (14) 7
6 4 (57) 3 (43) 0 (0) 7
7 4 (57) 2 (29) 1 (14) 7
8 5 (83) 1 (17) 0 (0) 6
9 5 (100) 0 (0) 0 (0) 5
10 4 (67) 1 (17) 1 (17) 6
11 4 (80) 1 (20) 0 (0) 5
12 5 (100) 0 (0) 0 (0) 5
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opportunity to cost the intervention, we prefer instead
to do this as part of a subsequent full randomised con-
trolled trial (RCT) in order to provide the most up to
date evidence of intervention cost, at a point after the
intervention has been through all processes of testing,
modification, and testing. Doing this at the feasibility
stage risks estimating the cost of an intervention that
may be adapted or changed as part of the feasibility trial,
and thus, the costs may not reflect the reality of the
intervention when tested in a later stage RCT.
Adverse events There were nineteen adverse events
among six participants (4× MTCM; 2× TAU), one of
which was a serious adverse event (1× MTCM). None
were related to the intervention.
Process evaluation
Focus groups and interviews with participants, staff, and
pharmacists
In focus groups conducted with participants in the
MTCM arm, participants were positive about the
telephone system. Participants welcomed the praise
messages (one message per day) and found them
encouraging, helpful, constructive, and supportive.
Participants found the tablet device easy and
straightforward to use and noted that it encouraged
greater and more positive interaction with their
pharmacist. The use of debit cards was well received,
and participants highlighted the importance of achieving
the weekly bonus payment. Staff prescribers in the MTI
group reported that the telephone system had a positive
impact on their service. The weekly emails they received
allowed for close monitoring of their patients,
maintaining a rapport with them and saving staff time
not having to call pharmacies. The email alerts enabled
them to know immediately of missed doses. Pharmacists
reported that the tablet device was quick and easy to
use, it became part of a routine, and did not impact on
the pharmacy. In interviews conducted with staff in all
three arms, staff acknowledged the low numbers of new
opiate users presenting to services. In particular, staff in
the TAU group considered the very low numbers of
opioid users presenting to the drug service during the
recruitment period to be “highly unusual” for their drug
service. Staff suggested changes to eligibility criteria in a
future confirmatory trial, specifically to include existing
OAT patients repeatedly missing doses as well as
patients prescribed buprenorphine.
Issues with the telephone system or debit card
There were only a few instances of participants being
unable to self-login at the pharmacy, and these were
quickly resolved early on in the study. Two participants
lost their mobile telephones over 82 days and were un-
able to receive text messages, and two participants lost
their debit cards which were easily replaced.
Discussion
CM delivered by mobile telephone to encourage
medication adherence with OAT was feasible to deliver,
well-liked by patients and drug service staff, and accept-
able to pharmacists. There was good consistency in re-
cording of pharmacy attendance and dose consumption
between patient self-login and pharmacy prescribing re-
cords. Weekly reports of attendance and early warning
of missed doses were also well-liked by patients and
drug service staff who reported a positive impact on pa-
tient care. While it was feasible to recruit drug services
and pharmacists, it was not feasible to recruit the target
number of 60 individuals entering OAT. Good rates of
follow-up and data completeness were achieved.
With the huge increase in mobile telephone use and
coverage, there has been interest in developing mobile
health interventions in general, including CM [25]. CM
has previously been adapted to be delivered remotely
with the aim of providing treatment to patients who are
not attending treatment services or attending
intermittently to support recovery. A recent systematic
review and meta-analysis of contingency management
delivered by mobile telephone concluded CM delivered
by mobile telephones is effective in reducing substance
use among patients with tobacco and alcohol use dis-
order [13]. There has been one previous study which
found mobile telephone delivered CM improved HIV
medication adherence among individuals with substance
use disorder and HIV [26]. This is the first study of mo-
bile telephone CM in the UK and the first targeted at
OAT patient’s adherence to medication.
Table 4 Retention in treatment at follow-up, by arm
N (%)
MTCM TAU Total
Retained in treatment Supervised same clinic 6 (75) 1 (50) 7 (70)
Different OST same clinic 1 (12) 1 (50) 2 (20)
Unknown Did not attend follow-up interview 1 (12) 0 (0) 1 (10)
Total 8 2 10
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Patient self-login at community pharmacies was ac-
ceptable and well-liked by patients, staff, and pharma-
cists. Patients found the tablet device easy and
straightforward to use and noted that it encouraged
greater and more positive interaction with their pharma-
cist. Regarding daily recording attendance and consump-
tion of medication, there was a 96% consistency between
patient self-logins and pharmacy dispending records.
However, this result should not be over-interpreted
given the small sample size. As we only have data from
MTCM and very few from TAU, we do not know if par-
ticipants not receiving incentives will login to tablet de-
vices. In particular, patients liked the reminders, the
message content, and the 6-day bonus system. Partici-
pants welcomed the praise messages and found them en-
couraging, helpful, constructive, and supportive.
Extracting data from the telephone system was
automated and would scale-up well. In contrast, Phar-
mOutcomes data (or equivalent) will need to be ob-
tained on a larger scale and in a consistent format that
can easily be imported into trial databases (i.e. avoiding
time-consuming manual cleaning and re-entry).
The automatic weekly reports of attendance and early
warning of missed doses provided to prescribers were an
innovative and useful clinical addition to mobile
telephone CM. They were well-liked by both patients
and staff. Allowing staff to closely monitor their patients,
maintain a rapport with them, and save them time nor-
mally spent calling pharmacies for updates on patient at-
tendance and missed doses. The early warning alerts
provided prescribers with an immediate report of missed
doses. Pharmacists are not usually asked to alert pre-
scribers when a patient has missed one or two doses, so
this function has obvious benefits in helping prescribers
to provide informed and responsive treatment. Patients
valued having evidence of their medication adherence.
While the study found that drug services and
pharmacies could successfully be recruited to a cluster
trial, only 10 of the target 60 participants were recruited.
The study was unable to recruit the target patient
population due to lower than expected numbers of
patients presenting for OAT, higher than expected
numbers receiving buprenorphine, and higher numbers
than expected of allied pharmacies, at the time of
designing the study. In interviews, staff at all services
acknowledged the low numbers of new opioid users
presenting to drug services, although the very low
numbers in TAU were considered highly unusual.
Moreover, screening at the MTR clinic was undertaken
over 6 weeks instead of the planned 12 due to
unexpected recruitment issues and thus limiting
numbers of potential participants.
Recruitment could be improved in a future
confirmatory trial by revising the study patient eligibility
criteria to target existing OAT patients who are
repeatedly missing doses of methadone and
buprenorphine and increase the number of participating
pharmacies for each drug clinic site. Staff considered
these to be important patient groups to target. We plan
to undertake some additional work in preparation for a
future main trial. This will include identifying the
numbers (and characteristics) of existing OAT
(methadone and buprenorphine) patients who miss 3 or
more days doses at drug clinics in England to ensure we
are able to recruit our revised target population. We will
use these data to conduct a sample size calculation for
inform a future trial.
When planning a future confirmatory trial, we propose
to (a) target a different population of existing clients in
OAT, including patients who have missed their OAT
doses for > 3 days or are receiving buprenorphine as well
as methadone; (b) increase the number of participating
pharmacies allied to each drug service; and (c) identify
alternative ways of accessing PharmOutcomes data/
supervised medication records and (d) ensure
participants not receiving incentives (in the reminder
Table 5 Progression criteria to a future confirmatory trial
Progression criteria Achieved yes/no
1. Recruitment of 3 drug services Yes
2. Recruitment of 2–3 pharmacies per clinic Yes
3. 60 participants enrolled (20 from each clinic over 12 weeks) No, only 10 participants enrolled
4. 50% target patients (presenting to participating drug services for
a new episode of OST) eligible and consented
No, only 9% of target population were eligible and consented due to low
numbers presenting for OST at all clinics and high numbers excluded due to
receiving buprenorphine and not attending a participating pharmacy
5. > 95% consistency in recording of pharmacy attendance
(comparing daily pharmacy dispensing records vs. patient self-
login)
Yes, achieved 96%
6. Rates of follow-up at 12 weeks (> 70%) Yes, achieved 90% (9/10)
7. Completion rates of economic data collection (> 70%) Yes, achieved 100%
8. Missing (< 10% missing data per questionnaire) Yes
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and TAU groups) login to tablet devices and there is a
high degree of accuracy with pharmacy dispensing and
supervision records (Table 5). These elements could be
assessed with an internal pilot. An internal pilot can also
help to identify unexpected recruitment issues.
Conclusions
Overall, while the intervention proved to be feasible to
implement and deliver and was well-liked by drug ser-
vice staff, pharmacists, and patients, recruitment rates
sufficient for a definitive trial were not feasible and re-
main a challenge to be addressed. Mobile telephone CM
to improve adherence to medication has shown promise,
and using technology to deliver interventions is at the
core of improving healthcare in NHS England’s Five
Year Forward View. We propose that a confirmatory
trial to assess the clinical and cost-effectiveness is now
needed.
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